Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Accured Expenses (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Change in Accured Expenses for 4 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 2422.64% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 542.58% year-over-year, with the annual reading at $6.3 million for FY2025, 542.58% up from the prior year.
  • Change in Accured Expenses hit $2.7 million in Q4 2025 for Taysha Gene Therapies, down from $5.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.0 million in Q3 2025 to a low of -$7.7 million in Q2 2022.
  • Historically, Change in Accured Expenses has averaged -$670750.0 across 4 years, with a median of -$498500.0 in 2022.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 2453.04% in 2023 and later skyrocketed 2422.64% in 2025.
  • Year by year, Change in Accured Expenses stood at -$747000.0 in 2022, then crashed by 170.01% to -$2.0 million in 2023, then skyrocketed by 105.26% to $106000.0 in 2024, then surged by 2422.64% to $2.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for TSHA at $2.7 million in Q4 2025, $5.0 million in Q3 2025, and $732000.0 in Q2 2025.